Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 34, Issue -, Pages 105-111Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2017.09.016
Keywords
-
Categories
Funding
- Canadian Institutes of Health Research
- Canada Foundation for Innovation
- Cystic Fibrosis Canada
Ask authors/readers for more resources
These are exciting times in the development of therapeutics for cystic fibrosis (CF). New correctors and potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) are being developed in academic laboratories and pharmaceutical companies, and the field is just beginning to understand their mechanisms of action. Studies of CFTR modulators are also yielding insight into the general principles and strategies that can be used when developing pharmacological chaperones, a new class of drugs. Combining two or even three correctors with a potentiator is an especially promising approach which should lead to further improvements in efficacy and clinical benefit for patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available